Home > Publications Database > Serum and cerebrospinal kappa free light chains in psychiatric syndromes with neuronal and paraneoplastic autoantibodies. > print

001     281861
005     20251218103439.0
024 7 _ |a 10.1016/j.bbr.2025.115858
|2 doi
024 7 _ |a pmid:41038324
|2 pmid
024 7 _ |a 0166-4328
|2 ISSN
024 7 _ |a 1872-7549
|2 ISSN
037 _ _ |a DZNE-2025-01234
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Groeger, Luise M
|b 0
245 _ _ |a Serum and cerebrospinal kappa free light chains in psychiatric syndromes with neuronal and paraneoplastic autoantibodies.
260 _ _ |a Amsterdam
|c 2026
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1762417249_10696
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Kappa free light chains (KFLC) are a surrogate parameter for intrathecal immunoglobulin G (IgG), immunoglobulin M (IgM) and immunoglobulin A (IgA) synthesis confirming neuroinflammation in the central nervous system (CNS). It is unclear whether KFLC can differentiate primary psychiatric disorders from neural autoantibody-associated psychiatric syndromes.We enrolled 76 patients with psychiatric diagnoses ICD-10 (International Classification of Diseases, 10th revision) (F00-09, F10-19, F20-29, F30-39, F40-49) and cerebrospinal fluid (CSF) as well as blood samples from our biobank. Commercial assays were used to determine neural autoantibodies. KFLC in serum and CSF samples were assessed by nephelometry (Siemens Atellica NEPH 630 analyzer). We calculated the relative intrathecal fraction (IF) of KFLC and the KFLC index using KFLC quotient and albumin quotient. Criteria for autoimmune encephalitis and autoimmune-mediated psychiatric syndromes were evaluated in patients to determine an autoimmune basis for the psychiatric symptoms.Neither the number of patients with elevated KFLC, a KFLC index nor the KFLC IF percentage served as an instrument for differentiating between autoantibody-positive (n = 18) and autoantibody-negative (n = 58) psychiatric patients. Patients with elevated KFLC levels in CSF had a higher proportion of lymphocytes than patients with non-elevated KFLC as a non-significant trend. We observed a non-significant trend towards higher CSF/serum IgM, but no trend for CSF/serum IgA or CSF/serum IgG ratio in patients with elevated KFLC levels than in those with non-elevated KFLC. No probable autoantibody-positive or seronegative autoimmune encephalitis was detected in patients. However, we observed an autoantibody-associated psychiatric syndrome in 6 out of 10 patients with elevated KFLC-IF, and the detection of elevated KFLC improved the diagnosis of probable autoimmune disease in 4 out of 10 patients (40 %).Elevated KFLC levels may indicate psychiatric patients presenting any intrathecal immunoglobulin synthesis and thus help to evaluate an autoimmune basis in psychiatric syndromes. Furthermore, it should be added as a novel criterion for intrathecal immunoglobulin synthesis in autoimmune-related psychiatric syndromes. Further large-scale research is needed to elucidate the role of KFLC in autoimmune-mediated psychiatric disorders and to verify the observed trends in CSF parameters in patients with elevated KFLC.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Autoantibodies
|2 Other
650 _ 7 |a Kappa free light chains
|2 Other
650 _ 7 |a Psychiatry
|2 Other
650 _ 7 |a Autoantibodies
|2 NLM Chemicals
650 _ 7 |a Immunoglobulin kappa-Chains
|2 NLM Chemicals
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Autoantibodies: blood
|2 MeSH
650 _ 2 |a Autoantibodies: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Mental Disorders: blood
|2 MeSH
650 _ 2 |a Mental Disorders: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Mental Disorders: immunology
|2 MeSH
650 _ 2 |a Mental Disorders: diagnosis
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Immunoglobulin kappa-Chains: blood
|2 MeSH
650 _ 2 |a Immunoglobulin kappa-Chains: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Encephalitis: immunology
|2 MeSH
650 _ 2 |a Encephalitis: blood
|2 MeSH
650 _ 2 |a Encephalitis: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Encephalitis: diagnosis
|2 MeSH
650 _ 2 |a Hashimoto Disease: blood
|2 MeSH
650 _ 2 |a Hashimoto Disease: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Hashimoto Disease: immunology
|2 MeSH
650 _ 2 |a Hashimoto Disease: diagnosis
|2 MeSH
650 _ 2 |a Biomarkers: blood
|2 MeSH
650 _ 2 |a Biomarkers: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Young Adult
|2 MeSH
700 1 _ |a Brinke, Kristina Auf dem
|b 1
700 1 _ |a Simou, Amina
|b 2
700 1 _ |a Luedecke, Daniel
|b 3
700 1 _ |a Maier, Hannah B
|b 4
700 1 _ |a Neyazi, Alexandra
|b 5
700 1 _ |a Gallinat, Jürgen
|b 6
700 1 _ |a Bleich, Stefan
|b 7
700 1 _ |a Skripuletz, Thomas
|b 8
700 1 _ |a Konen, Franz F
|b 9
700 1 _ |a Wiltfang, Jens
|0 P:(DE-2719)2811317
|b 10
|u dzne
700 1 _ |a Malchow, Berend
|b 11
700 1 _ |a Fitzner, Dirk
|b 12
700 1 _ |a Hansen, Niels
|b 13
700 1 _ |a CAP
|b 14
|e Collaboration Author
773 _ _ |a 10.1016/j.bbr.2025.115858
|g Vol. 496, p. 115858 -
|0 PERI:(DE-600)2013604-3
|p 115858
|t Behavioural brain research
|v 496
|y 2026
|x 0166-4328
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/281861/files/DZNE-2025-01234.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/281861/files/DZNE-2025-01234.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:281861
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)2811317
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-18
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BEHAV BRAIN RES : 2022
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-18
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-18
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-18
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-18
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-18
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-18
920 1 _ |0 I:(DE-2719)1410006
|k AG Wiltfang
|l Molecular biomarkers for predictive diagnostics of neurodegenerative diseases
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1410006
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21